Merck KGaA
Explore by topic
5-year stock timeline
2021
Belén Garijo became Chair of the Executive Board and CEO effective May 2021. [6,28] Performance Materials was renamed Electronics on 4 March 2021, with Peter Guenter and Matthias Heinzel joining management in early 2021 to lead Healthcare and Life Science respectively. [6]
The year delivered strong operational results: Group sales reached €19.7bn with EBITDA pre of €6.1bn (31.0% margin), EPS pre of €8.72, and a proposed dividend of €1.85. Net financial debt fell to €8.8bn. Management raised its business forecast multiple times throughout the year. [3,5]
Investors re-rated Merck KGaA away from a mixed cyclic/industrial holding toward a growth narrative, driven by Healthcare and Life Science momentum and visible execution. [3,5]
The stock rallied broadly across the year, moving from roughly €130–140 in early 2021 to a year-end close of €227, with intraday highs near €245 in late December. [44,5,46]
2022
Merck completed the acquisition of Exelead Inc. (CDMO) on 22 February 2022 for US$793m (≈€702m). [9] The company announced the purchase of the Mecaro chemical business on 17 August 2022, closing on 30 December 2022 for approximately €90m in total payments. [8,9] Erbi Biosystems Inc. was acquired on 1 December 2022 for €78m. [9]
Legal carve-outs and registrations for Merck Life Science KGaA and Merck Electronics KGaA were recorded in late 2022 (1 November and 29 December 2022) as preparatory steps for the operating company separation. FY 2022 Group net sales reached approximately €22.232bn. [12,9,16]
The narrative shifted from pure re-rating toward portfolio reshaping and M&A activity. Investors focused on integration execution—particularly CDMO capability via Exelead—while monitoring exposure to cyclical end-markets in semiconductor materials and electronics. M&A was viewed as strategically sound but execution-sensitive. [9,8,7]
The stock experienced material volatility and retracement from 2021 highs, with a mid-2022 low around €156 in June, followed by recovery into year-end (€175–180). The stock traded roughly €150–185 for the year. [44]
2023
Merck Life Science KGaA and related operating company structures went live on 1 January 2023 following the 2022 legal preparations. [12] The company announced the sale of phosphorescent OLED emitter IP assets to Universal Display Corporation on 3 May 2023. [11]
FY 2023 results showed Group net sales declining to approximately €21.0bn (−5.6% year-on-year), with profit after tax falling to around €2.83bn. Management attributed the weakness to expected declines in Covid-19-related demand, customer inventory destocking in Process Solutions, and a cyclical slowdown in semiconductor materials. [22,26]
Management labelled 2023 a transitional year. Investor narrative turned cautious as management touted the resilience of a multi-industry model while markets worried over cyclicality in Life Science and Electronics, and near-term earnings variability. [26,22]
A significant drawdown occurred: early 2023 levels near €185–190 fell to troughs around €140 in October–December (roughly a 25–30% decline from early-2023 highs), with occasional rebounds such as a November 2023 spike toward €160. The year closed in the mid-€140s. [44,22]
2024
The year saw continuation of post-restructuring and integration activity as the operating company separation effects persisted. No single large headline M&A transaction was recorded in sourced results for 2024; primary M&A activity in the sources clusters in 2022–2023 and then 2025. [12,9,11]
Investor narrative settled into a consolidation phase marked by watchfulness. Stakeholders awaited clear signs of cyclical recovery and evidence that the operating company separations and prior acquisitions were accretive. Sentiment was selective and performance-driven. [12,26]
The stock consolidated in a range-bound pattern, with January 2024 around €150 and trading generally inside a €140–€160 band throughout the year. [44]
2025
Merck announced a definitive agreement to acquire SpringWorks Therapeutics on 28 April 2025 for a cash offer of $47 per share, representing equity value of approximately $3.9bn (enterprise value roughly €3.0bn net of cash). The transaction signalled a sizable bolt-on to strengthen the oncology and rare-disease pipeline. [15,17]
The narrative shifted back toward M&A-driven pipeline building. Investors recognised a return to targeted, larger biotech acquisitions to supplement organic pipeline development. Market reaction was mixed as stakeholders balanced the price paid against expected pipeline value. [15,17]
After multi-year consolidation, 2025 trading remained well below 2021 peaks. Market attention focused on deal timing and execution as the principal catalyst for the next directional move. [44,46,15]
2026 (January–8 July)
Kai Beckmann was announced to succeed Belén Garijo as Chair of the Executive Board and CEO, effective May 2026. [36]
Continued integration and execution of prior M&A—particularly the SpringWorks acquisition announced in 2025—remained a strategic focus. [15,17]
The near-term investor narrative centred on leadership transition and watchfulness for M&A integration outcomes. Markets focused on how the new CEO will execute the stated strategy of pipeline M&A and realising operating company separation benefits while managing cyclicality risks. [36,15,12]
The current price of 141.75 as of 8 July 2026 remains materially below the 2021 year-end close of €227, a gap of roughly 38%, reflecting the multi-year re-rating and cyclicality effects across the period. [5]
Key risks and downside factors
Merck KGaA runs three separate operations: pharmaceuticals and biotech through Healthcare/EMD Serono, life science tools and bioprocessing via MilliporeSigma, and specialty materials for electronics through EMD Electronics. Competition is fragmented across these domains—large pharmaceutical companies pushing innovative medicines, established life-science suppliers competing on tools and bioprocessing capacity, and chemical firms vying for share in semiconductor and display materials. The company's risk surface is correspondingly broad. Drug development carries the usual regulatory and clinical uncertainties. Lab supplies face persistent margin compression and share erosion. Electronics materials demand swings with semiconductor and display cycles. Layered beneath are operational vulnerabilities—supply chain friction, manufacturing complexity, compliance burden—that matter more when margins are already thin.
- Regulatory and R&D risk: late-stage clinical failures, regulatory delays, or adverse safety data could materially reduce Healthcare segment revenues and pipeline value.
- Large pharmaceutical and life-science tools competitors pose a dual threat: they can siphon market share or drive down pricing, both of which compress margins across Healthcare and Life Science segments.
- Electronics and Performance Materials businesses carry inherent cyclicality. Semiconductor and display capital spending cycles drive demand volatility, while raw material and energy price swings create additional pressure on margins and top-line predictability. Revenue can shift sharply when either cycle turns.
- Global manufacturing operations create meaningful exposure to production disruptions, input scarcity, environmental and regulatory actions, and intellectual property or antitrust litigation—each capable of materially raising costs or liabilities.
Competitive landscape
Merck KGaA (MRK.XETRA) operates across three separate domains — Healthcare delivering prescription medicines, Life Science supplying lab reagents, instruments and bioprocessing capabilities, and Electronics/Performance Materials — which means its competitive landscape spans from global pharmaceutical giants to specialized life-science suppliers and chemicals manufacturers. The most intense pressure comes from established pharma players like Roche and Novartis, dominant life-science tools and CDMO operators such as Thermo Fisher, Danaher and Sartorius, and materials heavyweights like BASF. The portfolio's breadth protects against single-product concentration but introduces exposure to regulatory shifts, cyclical demand swings and raw material cost pressures across multiple markets.
| Company | Ticker |
|---|---|
| Thermo Fisher Scientific Inc. | TMO.NYSE |
| Danaher Corporation | DHR.NYSE |
| Sartorius AG | SRT.XETRA |
| Roche Holding AG | ROG.SIX |
| Novartis AG | NOVN.SIX |
Private competitors
- Rentschler Biopharma SE
- CordenPharma (private CDMO group)
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialPerformance Figures of Merck KGaA
Relative Performance vs Benchmarks
| Period | Merck KGaA | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | +3.13% | +1.42% | +1.72% |
| 3M | +29.80% | +24.63% | +19.54% |
| 6M | +12.70% | +13.58% | +4.40% |
| 1Y | +29.56% | +26.13% | +7.69% |
| 3Y | +2.00% | -58.47% | -74.98% |
| 5Y | -9.66% | -69.26% | -93.35% |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHistorical valuation trends
How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | 24.3 | 2.9 | 2.1 | 14.7 |
| 1Y ago | 16.6 | 2.2 | 1.6 | 12.5 |
| 3Y ago | 20.7 | 2.9 | 2.4 | 15.8 |
| 5Y ago | 26.9 | 4.0 | 3.8 | 16.1 |
Frequently Asked Questions
Where is the Merck KGaA stock traded?
What does Merck KGaA do?
What are the key metrics for MRK.XETRA?
How has Merck KGaA's stock price performed?
How is MRK.XETRA valued?
Does MRK.XETRA pay dividends?
What are the key risks when investing in MRK.XETRA?
- Regulatory and R&D risk: late-stage clinical failures, regulatory delays, or adverse safety data could materially reduce Healthcare segment revenues and pipeline value.
- Large pharmaceutical and life-science tools competitors pose a dual threat: they can siphon market share or drive down pricing, both of which compress margins across Healthcare and Life Science segments.
- Electronics and Performance Materials businesses carry inherent cyclicality. Semiconductor and display capital spending cycles drive demand volatility, while raw material and energy price swings create additional pressure on margins and top-line predictability. Revenue can shift sharply when either cycle turns.
- Global manufacturing operations create meaningful exposure to production disruptions, input scarcity, environmental and regulatory actions, and intellectual property or antitrust litigation—each capable of materially raising costs or liabilities.
Who are the main competitors of Merck KGaA?
- Thermo Fisher Scientific Inc. (TMO.NYSE)
- Danaher Corporation (DHR.NYSE)
- Sartorius AG (SRT.XETRA)
- Roche Holding AG (ROG.SIX)
- Novartis AG (NOVN.SIX)
When does Merck KGaA report earnings?
Key Metrics
Valuation Metrics
Profitability Metrics
Growth Metrics
Dividend history
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 2.20 EUR | 1.97% | 1.35% |
| 2025 | 2.20 EUR | 1.82% | |
| 2024 | 2.20 EUR | 1.45% | |
| 2023 | 2.20 EUR | 1.35% | |
| 2022 | 1.85 EUR | 1.05% | |
| 2021 | 1.40 EUR | 0.97% | |
| 2020 | 1.30 EUR | 1.23% | |
| 2020 | 1.30 EUR | 1.24% | |
| 2019 | 1.25 EUR | 1.31% | |
| 2018 | 1.25 EUR | 1.51% | |
| 2017 | 1.20 EUR | 1.11% | |
| 2016 | 1.05 EUR | 1.28% | |
| 2015 | 1.00 EUR | 0.95% | |
| 2014 | 0.95 EUR | 1.55% | |
| 2013 | 0.85 EUR | 1.46% |
Earnings history & estimates
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Historical earnings performance
Upcoming earnings report
Analyst estimates for upcoming periods
Key financial figures
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 21.10B | 21.16B | 20.99B | 22.23B | 19.69B |
| Operating income (EBIT) | 4.07B | 4.37B | 4.04B | 5.00B | 4.28B |
| Net income | 2.61B | 2.78B | 2.82B | 3.33B | 3.06B |
| Free cash flow | 2.35B | 2.40B | 1.76B | 2.45B | 3.19B |
| Total assets | 52.10B | 51.57B | 48.49B | 48.53B | 45.36B |
| Equity | 28.59B | 29.91B | 26.68B | 25.93B | 21.34B |
| Net debt | 9.23B | 8.12B | 7.96B | 9.00B | 9.26B |
PWP Leeway UG (haftungsbeschränkt)
